Clearmind Medicine Files International Patent for PTSD Psychedelics
Ticker: CMND · Form: 6-K · Filed: Sep 12, 2024 · CIK: 1892500
Sentiment: bullish
Topics: patent, psychedelics, PTSD, R&D
TL;DR
Clearmind & Yissum patenting new psychedelics for PTSD. Big news for mental health treatment.
AI Summary
Clearmind Medicine Inc. announced on September 12, 2024, that it and Yissum have filed an international patent application for novel psychedelic compounds designed to treat Post-Traumatic Stress Disorder (PTSD). This filing is part of their ongoing efforts to develop innovative treatments for mental health conditions.
Why It Matters
This patent filing could lead to new, effective treatments for PTSD, a condition affecting millions worldwide, potentially offering significant therapeutic advancements.
Risk Assessment
Risk Level: medium — The success of a patent application and the subsequent development and market approval of a new drug are subject to significant scientific, regulatory, and commercial risks.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the report and applicant
- Yissum (company) — Co-applicant for the patent
- September 12, 2024 (date) — Date of the press release and filing
- Post-Traumatic Stress Disorder (PTSD) (condition) — Target condition for the patented compounds
FAQ
What is the specific nature of the psychedelic compounds for which the patent application was filed?
The filing describes them as 'novel psychedelic compounds' for the treatment of PTSD, but specific chemical structures or formulations are not detailed in this 6-K filing.
What is the significance of filing an international patent application?
An international patent application allows Clearmind Medicine and Yissum to seek patent protection in multiple countries simultaneously, expanding the potential global reach of their invention.
What is Yissum's role in this collaboration?
Yissum is a partner in this venture, co-filing the international patent application with Clearmind Medicine for the psychedelic compounds.
What is the current stage of development for these compounds?
The filing indicates that a patent application has been submitted, suggesting the compounds are in the early stages of research and development, prior to clinical trials or market approval.
Does this filing include any financial details related to the patent or development?
No, this Form 6-K filing primarily incorporates a press release announcing the patent application and does not contain specific financial figures related to the patent or development costs.
Filing Stats: 271 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-09-12 16:01:18
Filing Documents
- ea0214343-6k_clearmind.htm (6-K) — 12KB
- ea021434302ex99-1_clearmind.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-078141.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: September 12, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3